|
Vector | Application | Outcome | >Reference |
|
Helper-dependent AdV expressing woodchuck IFN | Intravenous (portal vein) | Transient inhibition of WHV replication | Fiedler et al., 2004 [163] |
Helper-dependent AdV expressing woodchuck IFN | Intravenous (portal vein) | No effect | Fiedler et al., 2004 [163] |
AdV expressing woodchuck IFN in combination with clevudine (L-FMAU) and emtricitabine (FTC) | intravenous | T-cell infiltration and inflammation in the liver |
Jacquard et al., 2004 [164] |
No additional antiviral effect beyond the treatment with the nucleot(s)ide analogues |
AdV expressing woodchuck IFN and TNF in combination with clevudine (L-FMAU) | intravenous | Transient inhibition of WHV replication | Zhu et al., 2004 [165] |
High-capacity AdV expressing murine IL-12 under the control of a liver-specific inducible promoter | intrahepatic (via laparotomy) | Inhibition of WHV replication in the liver and decreased viral load in serum. |
Crettaz et al., 2009 [166] |
Induction of anti-WHs antibodies. |
The effect was observed only in animals with basal viremia lower than 1010 copies/mL. |
AdV expressing herpes simplex virus thimidine kinase combined with gancyclovir treatment | intratumoural (via laparotomy) | Necrotic areas in the tumour mass and in the liver. |
Bilbao et al., 2000 [167] |
No reduction in tumour volume. |
AdV expressing murine IL-12 and B7.1 molecule | intratumoural (via laparotomy and MRI guidance) | CD4+ and CD8+ T cell infiltration in the liver. |
Pützer et al., 2001 [168] |
Reduction in tumour volume. |
Semliki forest viral vector expressing murine IL-12 | intratumoural (via laparotomy) | Induction of T cell responses to tumour antigens. |
Rodriguez-Madoz et al., 2009 [75] |
Induction T cell responses to WHcAg and WHsAg. |
Dose-dependent, transient reduction in tumour volume. |
|